Shares pursuant to, and who had properly exercised and perfected their demand for appraisal under and complied in all respects with, Section 262 of the DGCL and who, as of the Effective Time, had not withdrawn in accordance with Section 262 their demand for appraisal under Section 262 with respect to such Shares), was cancelled and automatically converted into the right to receive the Offer Consideration, in accordance with the Merger Agreement.
Pursuant to the terms of the Merger Agreement, at the Effective Time, each compensatory option to purchase Shares (a “Company Stock Option”), whether vested or unvested, which was outstanding immediately prior to the Effective Time became fully vested and was canceled in exchange for the right of the holder of such Company Stock Option to receive (subject to any applicable withholdings) an amount in cash equal to the product of (i) the excess (if any) of the Offer Consideration over the per share exercise price of such Option, multiplied by (ii) the total number of Shares subject to such Company Stock Option. Additionally, at the Effective Time, each award of restricted stock units representing the right to vest in and be issued Shares by Inari (a “Company RSU Award”) whether vested or unvested, which was outstanding immediately prior to the Effective Time was canceled in exchange for the right of the holder of such Company RSU Award to receive (subject to any applicable withholdings) an amount in cash equal to the product of (i) the Offer Consideration, multiplied by (ii) the total number of Shares subject to such Company RSU Award, together with any accrued and unpaid dividends corresponding to such Company RSU Award. For purposes of the foregoing clause (ii), the total number of Shares subject to a performance-based Company RSU Award was based on deemed achievement of maximum performance.
The total aggregate consideration paid by Merger Sub in the transaction was approximately $4.94 billion in cash. Stryker and Merger Sub funded the Offer and the Merger (including payments for Company Stock Options and Company RSUs, and net of cash on hand of Inari and its subsidiaries) from a combination of sources, including (a) available cash and cash equivalents of Stryker and its subsidiaries and (b) debt financings.
The foregoing description of the Merger Agreement and related transactions does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, a copy of which was filed as Exhibit 2.1 to Inari’s Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 6, 2025 and is incorporated herein by reference.
Item 1.02. |
Termination of a Material Definitive Agreement. |
In connection with the consummation of the Merger, effective as of the Effective Time, Inari terminated the Inari Medical, Inc. 2020 Incentive Award Plan and the Inari Medical, Inc. 2011 Equity Incentive Plan. Additionally, in connection with the consummation of the Merger, effective as of February 11, 2025, Inari terminated the Inari Medical, Inc. Amended and Restated 2020 Employee Stock Purchase Plan.
In connection with the consummation of the Merger, Stryker paid or caused to be paid, on behalf of Inari, all amounts necessary to satisfy and discharge in full the then-outstanding obligations of Inari under that certain Loan, Guaranty and Security Agreement, dated as of September 4, 2020, by and among Inari, Inari Medical International, Inc., the lenders from time to time party thereto and Bank of America, N.A., as agent (as amended, restated, supplemented or otherwise modified from time to time, together with all related credit documentation, the “Credit Facility”) and to terminate the Credit Facility and all commitments thereunder.
The disclosures under the Introductory Note are incorporated herein by reference.
Item 2.01. |
Completion of Acquisition or Disposition of Assets. |
The disclosures under the Introductory Note, Item 3.01, Item 5.01 and Item 5.03 are incorporated herein by reference.
Item 3.01. |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On February 19, 2025, Inari (i) notified The Nasdaq Global Select Market (“Nasdaq”) of the consummation of the Merger and (ii) requested that Nasdaq (x) suspend trading of the Shares, effective prior to market open on February 19, 2025, and (y) file with the SEC a Form 25 Notification of Removal from Listing and/or Registration to delist and deregister the Shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Inari intends to file with the SEC a Certification and Notice of Termination of Registration on Form 15 under